Gemtesa (vibegron) has a generally favorable safety profile for treating overactive bladder. In clinical trials, side effects were mild and occurred at low rates, and a dedicated blood pressure study found no clinically meaningful effects on heart rate or blood pressure compared to placebo. It also avoids the cognitive risks linked to older overactive bladder medications. That said, there are specific situations and drug interactions worth knowing about.
Common Side Effects
In the main clinical trial of 545 adults taking Gemtesa, the most frequently reported side effects were headache (4.0%), nasopharyngitis (2.8%), diarrhea (2.2%), nausea (2.2%), and upper respiratory tract infection (2.0%). For context, even headache, the most common complaint, only affected about 1 in 25 people, and placebo rates for the same symptoms were not far behind (2.4% for headache, for example). Most people tolerate the medication without notable issues.
A separate trial focused specifically on men with both overactive bladder and enlarged prostate found a slightly different pattern. Urinary tract infection occurred in 2.5% of those on Gemtesa versus 2.2% on placebo. Hypertension was reported in 9.0% of the Gemtesa group and 8.3% of the placebo group, though the definition used was broad, capturing any blood pressure increase above a set threshold at two consecutive visits.
Long-Term Safety Over One Year
An extension study followed patients taking Gemtesa for up to 52 weeks. No new safety concerns emerged beyond what shorter trials showed. The additional side effects reported in 2% or more of patients during that longer period were urinary tract infection (6.6%) and bronchitis (2.9%). The urinary tract infection rate is notable but not unusual for a population already dealing with bladder dysfunction, which carries its own baseline risk for these infections.
Cardiovascular Effects
Because Gemtesa works by activating a receptor that also exists in blood vessels, cardiovascular safety was a real question during development. A randomized, double-blind study specifically measuring 24-hour ambulatory blood pressure put this concern to rest. After 28 days of treatment, there were no statistically significant or clinically relevant differences in daytime or 24-hour systolic blood pressure, diastolic blood pressure, or heart rate between Gemtesa and placebo. A small number of patients in both groups had hypertension flagged as an adverse event (5 on Gemtesa, 4 on placebo), but none of the cases in the Gemtesa group were considered related to the medication.
Cognitive Safety Compared to Older Medications
This is one of the most important safety advantages Gemtesa has. Older overactive bladder drugs (anticholinergics like oxybutynin and tolterodine) block a chemical messenger in the brain that plays a role in memory and cognition. Gemtesa works through an entirely different mechanism and does not cross into the brain in the same way.
A large Japanese study of over 38,000 adults aged 65 and older with overactive bladder compared dementia risk between those taking anticholinergics and those taking a beta-3 agonist (the same drug class as Gemtesa). Anticholinergic users had a 22% higher risk of being diagnosed with dementia during follow-up. That increased risk held up even after the researchers adjusted for other health factors. If you’re an older adult or someone concerned about cognitive health, this distinction between drug classes is significant.
Urinary Retention Risk
Urinary retention, the inability to fully empty your bladder, has been reported with Gemtesa, though it occurred in fewer than 2% of patients in clinical trials. The risk is higher in two specific groups: people with bladder outlet obstruction (a physical blockage that already makes urination difficult) and people who take Gemtesa alongside an anticholinergic bladder medication. If you fall into either category, you should be aware of symptoms like difficulty starting urination, a weak stream, or a feeling that your bladder isn’t emptying. Urinary retention requires stopping the medication.
Drug Interaction With Digoxin
Gemtesa has one well-documented drug interaction that requires active management. If you take digoxin (a heart medication), Gemtesa increases the amount of digoxin circulating in your body by about 21% at peak levels and 11% overall. Since digoxin has a narrow range between an effective dose and a toxic one, this matters. Your digoxin levels should be checked before starting Gemtesa and monitored periodically while you take it, so your prescriber can adjust the digoxin dose if needed. The same monitoring applies when you stop Gemtesa, since digoxin levels will shift again.
Dosing and Practical Details
Gemtesa is taken as a single 75 mg tablet once daily, with or without food. There is no dose adjustment required. For people who have trouble swallowing pills, the tablet can be crushed and mixed with about a tablespoon of applesauce, then taken immediately with a glass of water.
Pregnancy, Breastfeeding, and Children
Gemtesa has not been studied in pregnant or breastfeeding women, so there is no human safety data for these groups. It is also not approved for use in children. Safety and effectiveness in pediatric patients have not been established.